How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 177-188

  Wunderink, Richard G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Community acquired MRSA; Exotoxins; Linezolid; Methicillin resistance; Panton Valentine leukocidin; Pneumonia; Staphylococcus aureus; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; METICILLIN; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PANTON VALENTINE LEUKOCIDIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

2009 H1N1 INFLUENZA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; ENDEMIC DISEASE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION RISK; INFECTIOUS PNEUMONIA; LIFE EXPECTANCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SKIN INFECTION; TOXIN SYNTHESIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS;

EID: 84873582490     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.006     Document Type: Review

References (44)

1. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005, 352(14):1485-1487.
2. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7(9):629-641.
3. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416.
4. Dufour P., Gillet Y., Bes M., et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002, 35(7):819-824.
5. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359(9308):753-759.
6. Kallen A.J., Reed C., Patton M., et al. Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006-2007. Epidemiol Infect 2010, 138(5):666-672.
7. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006, 355(7):666-674.
8. Kallen A.J., Brunkard J., Moore Z., et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009, 53(3):358-365.
9. Lobo L.J., Reed K.D., Wunderink R.G. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010, 138(1):130-136.
10. Thomas R., Ferguson J., Coombs G., et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology 2011, 16(6):926-931.
11. Jain SS, Wunderink RG, Fakhran S, et al. Etiology of community-acquired pneumonia among hospitalized adults in the United States: preliminary data from the CDC Etiology of Pneumonia in the Community (EPIC) Study. Abstract 676, Presented ID Week, San Diego, October, 2012.
12. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
13. Kollef M.H., Shorr A., Tabak Y.P., et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128(6):3854-3862.
14. Micek S.T., Kollef K.E., Reichley R.M., et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51(10):3568-3573.
15. Labelle A.J., Arnold H., Reichley R.M., et al. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 2010, 137(5):1130-1137.
16. Carratala J., Mykietiuk A., Fernandez-Sabe N., et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007, 167(13):1393-1399.
17. Wilson B.Z., Anzueto A., Restrepo M.I., et al. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med 2012, 40(8):2310-2314.
18. Hadler J.L., Petit S., Mandour M., et al. Trends in invasive infection with methicillin-resistant Staphylococcus aureus, Connecticut, USA, 2001-2010. Emerg Infect Dis 2012, 18(6):917-924.
19. von Eiff C., Becker K., Machka K., et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001, 344(1):11-16.
20. Bogaert D., van Belkum A., Sluijter M., et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004, 363(9424):1871-1872.
21. Rice T.W., Rubinson L., Uyeki T.M., et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012, 40(5):1487-1498.
22. Chen S.Y., Liao C.H., Wang J.L., et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis 2012, 55(10):1329-1337.
23. Gillet Y., Vanhems P., Lina G., et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45(3):315-321.
24. Van De Griend P., Herwaldt L.A., Alvis B., et al. Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA. Emerg Infect Dis 2009, 15(10):1582-1589.
25. Kett D.H., Cano E., Quartin A.A., et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11(3):181-189.
26. Ewig S., Welte T., Chastre J., et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10(4):279-287.
27. Robicsek A., Suseno M., Beaumont J.L., et al. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol 2008, 46(2):588-592.
28. Fagon J., Patrick H., Haas D.W., et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000, 161(3 Pt 1):753-762.
29. Pertel P.E., Bernardo P., Fogarty C., et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008, 46(8):1142-1151.
30. File T.M., Low D.E., Eckburg P.B., et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii19-iii32.
31. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54(5):621-629.
32. Kollef M.H., Rello J., Cammarata S.K., et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30(3):388-394.
33. Rubinstein E., Cammarata S., Oliphant T., et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001, 32(3):402-412.
34. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124(5):1789-1797.
35. Wunderink R.G., Cammarata S.K., Oliphant T.H., et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003, 25(3):980-992.
36. Wunderink R.G., Mendelson M.H., Somero M.S., et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008, 134(6):1200-1207.
37. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195(2):202-211.
38. Bernardo K., Pakulat N., Fleer S., et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004, 48(2):546-555.
39. Stevens D.L., Wallace R.J., Hamilton S.M., et al. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006, 42(5):729-730.
40. Hamilton L.A., Christopher Wood G., Magnotti L.J., et al. Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid. J Trauma Acute Care Surg 2012, 72(6):1478-1483.
41. Haque N.Z., Zuniga L.C., Peyrani P., et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138(6):1356-1362.
42. Jeffres M.N., Isakow W., Doherty J.A., et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29(6):1107-1115.
43. Jung Y.J., Koh Y., Hong S.B., et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010, 38(1):175-180.
44. Kalil A.C., Murthy M.H., Hermsen E.D., et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010, 38(9):1802-1808.